3
Clinical Trials associated with KL0011034 / Not yet recruitingPhase 1 A Single-Center, Randomized, Open-Label, Three-Sequence, Three-Period Crossover Study to Evaluate the Drug-Drug Interaction Between KL0011034 Injection and Alfentanil Hydrochloride Injection
To evaluate the pharmacokinetic interaction of KL0011034 injection in combination with alfentanil hydrochloride injection.To evaluate the safety and tolerability of KL0011034 injection in combination with alfentanil hydrochloride injection.To evaluate the effect of alfentanil hydrochloride injection on the pharmacodynamics of KL0011034 injection.
A Single-center, Randomized, Double-blind, Placebo-Controlled,Positive-Controlled, Dose-Escalation, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of a Single Dose Injection of KL0011034 Injection in Healthy Chinese Volunteers
To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single intravenous doses of KL0011034 injection in healthy volunteers.
A study evaluated the safety, tolerability and efficacy of a single administration of KL0011034 injection in healthy subjects Single-center, randomized, double-blind, placebo-controlled, positive drug-controlled, dose escalation of pharmacokinetic characteristics Phase I clinical study
100 Clinical Results associated with KL0011034
100 Translational Medicine associated with KL0011034
100 Patents (Medical) associated with KL0011034
100 Deals associated with KL0011034